Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 )
The summary for the Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 ) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 ): The purpose of this FOA is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.
Federal Grant Title: | Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 ) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-18-510 |
Type of Funding: | Grant |
CFDA Numbers: | 93.279 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | May 7th, 2020 |
Original Application Deadline: | May 7th, 2020 |
Posted Date: | December 18th, 2017 |
Creation Date: | December 18th, 2017 |
Archive Date: | June 12th, 2020 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | December 18th, 2017 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PAR-18-510.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
- • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...
- • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
- • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
- • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...
- • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
- • Drug Abuse Aspects of Hiv/Aids and Other Infections
- • Epidemiology of Drug Abuse
- More Grants from the National Institutes of Health
- • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...
- • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...
- • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
- • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...
- • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...